Nurix Historical Balance Sheet

NRIX Stock

USD 20.02 0.37 1.88%

Trend analysis of Nurix Therapeutics balance sheet accounts such as Total Stockholder Equity of 636.3 M provides information on Nurix Therapeutics' total assets, liabilities, and equity, which is the actual value of Nurix Therapeutics to its prevalent stockholders. By breaking down trends over time using Nurix Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Nurix Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nurix Therapeutics is a good buy for the upcoming year.

Nurix Therapeutics Inventory

(940,500)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

About Nurix Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Nurix Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Nurix Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Nurix Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Nurix currently owns. An asset can also be divided into two categories, current and non-current.

Nurix Therapeutics Balance Sheet Chart

At this time, Nurix Therapeutics' Non Current Liabilities Total is fairly stable compared to the past year. Capital Surpluse is likely to rise to about 856.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 64.9 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Nurix Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Nurix Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Nurix Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nurix Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Nurix Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Nurix Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.At this time, Nurix Therapeutics' Non Current Liabilities Total is fairly stable compared to the past year. Capital Surpluse is likely to rise to about 856.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 64.9 M in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	24.9M	38.0M	43.7M	45.9M
Total Assets	355.6M	669.3M	769.7M	808.2M

Other Current Liab Total Assets

Nurix Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.95	0.87	1.0	0.76	0.86	0.91	0.7	-0.77	-0.91	0.97	0.88	0.7	0.8	0.21	0.99	0.87	0.82	0.98	-0.15	0.95	0.92	0.98	0.88	1.0	0.9
Other Current Liab	0.95		0.88	0.94	0.6	0.75	0.97	0.68	-0.59	-0.97	0.98	0.76	0.48	0.81	0.04	0.98	0.79	0.86	0.99	-0.22	0.92	0.83	0.99	0.87	0.94	0.98
Total Current Liabilities	0.87	0.88		0.86	0.59	0.88	0.92	0.86	-0.51	-0.93	0.87	0.78	0.58	0.93	0.03	0.86	0.91	0.9	0.87	-0.23	0.91	0.93	0.9	0.92	0.86	0.88
Total Stockholder Equity	1.0	0.94	0.86		0.76	0.86	0.9	0.7	-0.78	-0.9	0.97	0.89	0.7	0.79	0.23	0.99	0.87	0.81	0.98	-0.18	0.94	0.91	0.98	0.86	1.0	0.88
Other Liab	0.76	0.6	0.59	0.76		0.85	0.6	0.44	-0.83	-0.59	0.64	0.84	0.86	0.61	0.52	0.68	0.84	0.64	0.65	0.41	0.78	0.8	0.66	0.77	0.76	0.54
Net Tangible Assets	0.86	0.75	0.88	0.86	0.85		0.79	0.81	-0.74	-0.79	0.76	0.88	0.86	0.86	0.37	0.8	0.99	0.78	0.78	0.01	0.93	0.97	0.81	0.89	0.86	0.71
Property Plant And Equipment Net	0.91	0.97	0.92	0.9	0.6	0.79		0.77	-0.47	-0.98	0.95	0.69	0.54	0.9	-0.06	0.93	0.83	0.89	0.94	-0.14	0.95	0.86	0.96	0.92	0.9	0.98
Current Deferred Revenue	0.7	0.68	0.86	0.7	0.44	0.81	0.77		-0.38	-0.72	0.67	0.59	0.63	0.8	0.1	0.66	0.8	0.59	0.67	-0.32	0.79	0.79	0.71	0.74	0.7	0.71
Net Debt	-0.77	-0.59	-0.51	-0.78	-0.83	-0.74	-0.47	-0.38		0.52	-0.63	-0.92	-0.7	-0.38	-0.73	-0.72	-0.71	-0.44	-0.67	-0.02	-0.66	-0.68	-0.65	-0.55	-0.78	-0.46
Retained Earnings	-0.91	-0.97	-0.93	-0.9	-0.59	-0.79	-0.98	-0.72	0.52		-0.94	-0.73	-0.48	-0.89	0.03	-0.93	-0.83	-0.92	-0.95	0.18	-0.93	-0.87	-0.96	-0.9	-0.9	-0.97
Accounts Payable	0.97	0.98	0.87	0.97	0.64	0.76	0.95	0.67	-0.63	-0.94		0.79	0.55	0.79	0.03	0.99	0.79	0.86	0.99	-0.18	0.91	0.85	0.99	0.88	0.97	0.96
Cash	0.88	0.76	0.78	0.89	0.84	0.88	0.69	0.59	-0.92	-0.73	0.79		0.7	0.65	0.54	0.85	0.88	0.71	0.81	-0.04	0.81	0.87	0.81	0.8	0.89	0.68
Non Current Assets Total	0.7	0.48	0.58	0.7	0.86	0.86	0.54	0.63	-0.7	-0.48	0.55	0.7		0.64	0.38	0.58	0.82	0.5	0.55	0.18	0.75	0.8	0.58	0.65	0.7	0.42
Non Currrent Assets Other	0.8	0.81	0.93	0.79	0.61	0.86	0.9	0.8	-0.38	-0.89	0.79	0.65	0.64		-0.09	0.77	0.9	0.91	0.79	-0.11	0.92	0.92	0.83	0.89	0.79	0.82
Other Assets	0.21	0.04	0.03	0.23	0.52	0.37	-0.06	0.1	-0.73	0.03	0.03	0.54	0.38	-0.09		0.15	0.31	-0.12	0.09	0.17	0.17	0.18	0.09	0.09	0.23	-0.06
Cash And Short Term Investments	0.99	0.98	0.86	0.99	0.68	0.8	0.93	0.66	-0.72	-0.93	0.99	0.85	0.58	0.77	0.15		0.82	0.83	1.0	-0.21	0.92	0.87	0.99	0.86	0.99	0.93
Common Stock Total Equity	0.87	0.79	0.91	0.87	0.84	0.99	0.83	0.8	-0.71	-0.83	0.79	0.88	0.82	0.9	0.31	0.82		0.83	0.8	0.0	0.94	0.98	0.84	0.91	0.87	0.75
Common Stock Shares Outstanding	0.82	0.86	0.9	0.81	0.64	0.78	0.89	0.59	-0.44	-0.92	0.86	0.71	0.5	0.91	-0.12	0.83	0.83		0.84	0.02	0.86	0.88	0.86	0.93	0.81	0.87
Short Term Investments	0.98	0.99	0.87	0.98	0.65	0.78	0.94	0.67	-0.67	-0.95	0.99	0.81	0.55	0.79	0.09	1.0	0.8	0.84		-0.24	0.92	0.86	1.0	0.86	0.98	0.95
Non Current Liabilities Total	-0.15	-0.22	-0.23	-0.18	0.41	0.01	-0.14	-0.32	-0.02	0.18	-0.18	-0.04	0.18	-0.11	0.17	-0.21	0.0	0.02	-0.24		-0.09	-0.08	-0.22	0.13	-0.18	-0.17
Capital Surpluse	0.95	0.92	0.91	0.94	0.78	0.93	0.95	0.79	-0.66	-0.93	0.91	0.81	0.75	0.92	0.17	0.92	0.94	0.86	0.92	-0.09		0.95	0.95	0.92	0.94	0.89
Other Current Assets	0.92	0.83	0.93	0.91	0.8	0.97	0.86	0.79	-0.68	-0.87	0.85	0.87	0.8	0.92	0.18	0.87	0.98	0.88	0.86	-0.08	0.95		0.88	0.92	0.91	0.8
Other Stockholder Equity	0.98	0.99	0.9	0.98	0.66	0.81	0.96	0.71	-0.65	-0.96	0.99	0.81	0.58	0.83	0.09	0.99	0.84	0.86	1.0	-0.22	0.95	0.88		0.88	0.98	0.96
Total Liab	0.88	0.87	0.92	0.86	0.77	0.89	0.92	0.74	-0.55	-0.9	0.88	0.8	0.65	0.89	0.09	0.86	0.91	0.93	0.86	0.13	0.92	0.92	0.88		0.86	0.89
Net Invested Capital	1.0	0.94	0.86	1.0	0.76	0.86	0.9	0.7	-0.78	-0.9	0.97	0.89	0.7	0.79	0.23	0.99	0.87	0.81	0.98	-0.18	0.94	0.91	0.98	0.86		0.88
Property Plant And Equipment Gross	0.9	0.98	0.88	0.88	0.54	0.71	0.98	0.71	-0.46	-0.97	0.96	0.68	0.42	0.82	-0.06	0.93	0.75	0.87	0.95	-0.17	0.89	0.8	0.96	0.89	0.88

Click cells to compare fundamentals

Nurix Therapeutics Account Relationship Matchups

Nurix Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	476.8M	416.8M	355.6M	669.3M	769.7M	808.2M
Other Current Liab	10.6M	16.8M	24.9M	38.0M	43.7M	45.9M
Total Current Liabilities	66.3M	70.7M	87.0M	95.9M	110.2M	64.9M
Total Stockholder Equity	342.3M	303.7M	200.5M	527.0M	606.0M	636.3M
Other Liab	37.4M	61.5M	59.0M	36.0M	41.4M	42.9M
Net Tangible Assets	(57.7M)	290.3M	342.3M	303.7M	349.3M	185.2M
Property Plant And Equipment Net	25.3M	29.5M	48.0M	45.9M	52.8M	55.4M
Current Deferred Revenue	41.2M	37.6M	48.1M	38.4M	44.1M	37.1M
Net Debt	(67.5M)	(52.5M)	(24.0M)	(81.7M)	(73.5M)	(77.2M)
Retained Earnings	(220.9M)	(401.3M)	(545.2M)	(738.8M)	(664.9M)	(631.6M)
Accounts Payable	6.7M	5.1M	6.4M	11.5M	13.2M	13.9M
Cash	80.5M	64.5M	54.6M	110.0M	126.5M	76.9M
Non Current Assets Total	165.7M	98.3M	60.1M	50.0M	57.4M	75.6M
Non Currrent Assets Other	3.1M	4.9M	4.7M	4.1M	4.7M	2.8M
Other Assets	317K	91.2M	3.1M	4.9M	5.7M	5.4M
Cash And Short Term Investments	295.7M	309.1M	287.9M	609.6M	701.0M	736.1M
Common Stock Total Equity	4K	39K	45K	47K	54.1K	30.4K
Common Stock Shares Outstanding	42.9M	48.6M	54.3M	67.1M	77.2M	44.6M
Short Term Investments	215.2M	244.7M	233.3M	499.6M	574.5M	603.3M
Liabilities And Stockholders Equity	476.8M	416.8M	355.6M	669.3M	769.7M	808.2M
Non Current Liabilities Total	68.2M	42.4M	68.1M	46.5M	41.8M	48.2M
Capital Surpluse	2.7M	393.8M	563.8M	709.2M	815.6M	856.4M
Other Current Assets	9.4M	9.3M	7.6M	9.8M	11.3M	7.1M
Other Stockholder Equity	563.8M	709.2M	746.3M	1.3B	1.5B	1.5B
Total Liab	134.5M	113.1M	155.1M	142.4M	163.7M	131.2M
Net Invested Capital	342.3M	303.7M	200.5M	527.0M	606.0M	636.3M
Property Plant And Equipment Gross	25.3M	29.5M	74.2M	80.4M	92.5M	97.1M
Total Current Assets	311.1M	318.4M	295.5M	619.4M	712.3M	747.9M
Accumulated Other Comprehensive Income	(608K)	(4.3M)	(655K)	150K	135K	141.8K
Capital Stock	45K	47K	49K	76K	87.4K	91.8K
Non Current Liabilities Other	1.7M	850K	68.2M	42.4M	48.8M	25.2M
Net Working Capital	244.9M	247.8M	208.5M	523.5M	602.1M	632.2M
Short Term Debt	7.7M	11.1M	13.9M	8.0M	9.2M	8.8M
Common Stock	45K	47K	49K	76K	87.4K	91.8K
Property Plant Equipment	3.9M	6.7M	25.3M	17.2M	19.7M	12.6M
Capital Lease Obligations	13.0M	12.0M	30.6M	28.3M	32.5M	18.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nurix Historical Balance Sheet

Nurix Therapeutics Inventory

(940,500)

About Nurix Balance Sheet Analysis

Nurix Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Nurix Therapeutics balance sheet Correlations

Nurix Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nurix Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Nurix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Short Term Investments	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 1.0	Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets

Retained Earnings	- 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab
Other Stockholder Equity	- 0.96	Retained Earnings
Short Term Investments	- 0.95	Retained Earnings
Accounts Payable	- 0.94	Retained Earnings